Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 13123 [2017-04626]
Download as PDF
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 82, No. 45 / Thursday, March 9, 2017 / Notices
and insufficient levels of evidence to the
following:
‘‘Data sets classified as sufficient are
those that include human and/or animal
studies conducted using standardized
protocols and that provide complete
descriptions of the exposure conditions
and study findings. Data sets classified
as limited are those that include human
and/or animal studies conducted using
non-standardized protocols or that
provide incomplete descriptions of the
exposure conditions or study findings.
Data sets classified as insufficient are
those that include human and/or animal
studies conducted using nonstandardized protocols and that provide
incomplete descriptions of the exposure
conditions and study findings. Data sets
that receive the insufficient ranking will
not be used as the basis for the NIOSH
skin notation.’’
Evaluation of dose-related effects in
studies with limited or insufficient
evidence, mechanistic data, and
analogous chemical properties may be
factored into the classification scheme
for determining the level of evidence for
identified studies. Data sets that provide
insufficient evidence will not be used as
the basis for the NIOSH skin notation
but, in some cases, may provide
information to support or contradict
evidence for the skin notation.
For data sets with conflicting
findings, an overall determination based
on the body of evidence will be
developed by evaluating data adequacy,
reliability and relevance, and assessing
each study’s quality of evidence. The
studies with the best quality and
validity to support the notation are
identified and cited in the individual
Skin Notation Profile documents.
NIOSH seeks comments on proposed
changes as described above.
DATES: Comments must be submitted on
or before April 10, 2017.
ADDRESSES: You may submit comments,
identified by CDC–2017–0017 and
docket number NIOSH 153–D, by any of
the following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: National Institute for
Occupational Safety and Health, NIOSH
Docket Office, 1090 Tusculum Avenue,
MS C–34, Cincinnati, Ohio 45226–1998.
Instructions: All information received
in response to this notice must include
the agency name and docket number
[CDC–2017–0017; NIOSH 153–D]. All
relevant comments received will be
posted without change to
www.regulations.gov, including any
personal information provided. For
access to the docket to read background
VerDate Sep<11>2014
17:43 Mar 08, 2017
Jkt 241001
documents or comments received, go to
www.regulations.gov. For access to the
original docket [NIOSH–153] to view
background documents or comments
received, go to https://www.cdc.gov/
niosh/docket/archive/docket153.html.
All information received in response to
this notice will be available for public
examination and copying at the NIOSH
Docket Office, 1150 Tusculum Avenue,
Room 155, Cincinnati, OH 45226–1998.
FOR FURTHER INFORMATION CONTACT:
Naomi Hudson or G. Scott Dotson,
NIOSH, Education and Information
Division, Robert A. Taft Laboratories,
1190 Tusculum Ave, MS C–32,
Cincinnati, OH 45226, email: iuz8@
cdc.gov or fya8@cdc.gov.
In 2009,
NIOSH published Current Intelligence
Bulletin 61—A Strategy for assigning
New NIOSH Skin Notations [NIOSH
2009–147; https://www.cdc.gov/niosh/
docs/2009-147/pdfs/2009-147.pdf]. The
CIB presents a strategic framework that
is a form of hazard identification that
ensures that the assigned skin notations
reflect the contemporary state of
scientific knowledge, provides
transparency behind the assignment
process, communicates the hazards of
chemical exposures of the skin, and
meets the needs of health professionals,
employers, and others interested in
protecting workers from chemical
contact with the skin. Published Skin
Notation Profile documents are
available at https://www.cdc.gov/niosh/
topics/skin/skin-notation_profiles.html.
SUPPLEMENTARY INFORMATION:
Frank Hearl,
Chief of Staff, National Institute for
Occupational Safety and Health, Centers for
Disease Control and Prevention.
[FR Doc. 2017–04628 Filed 3–8–17; 8:45 am]
13123
1:00 p.m.–5:00 p.m.,
EDT, April 11, 2017 (Closed).
PLACE: Teleconference.
STATUS: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
MATTERS FOR DISCUSSION: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Cooperative Agreement on Global
Occupational Health with the World
Health Organization (WHO)’’, RFA–
OH17–1701.
CONTACT PERSON FOR MORE INFORMATION:
Nina Turner, Ph.D., Scientific Review
Officer, NIOSH, CDC, 1095 Willowdale
Road, Mailstop G905, Morgantown,
West Virginia 26506, Telephone: (304)
285–5976.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
TIME AND DATE:
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–04626 Filed 3–8–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Advisory Committee to the Director
(ACD), Centers for Disease Control and
Prevention (CDC)
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
RFA–OH17–1701, Cooperative
Agreement on Global Occupational
Health with the World Health
Organization (WHO).
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned committee:
Time and Date: 8:30 a.m.–3:00 p.m.,
EDT, April 20, 2017.
Place: CDC, Building 19, Auditorium
B3, 1600 Clifton Road NE., Atlanta,
Georgia 30329.
Status: Open to the public, limited
only by the seating and phone lines
available. The meeting room
accommodates approximately 60
people. Advance registration for in-
E:\FR\FM\09MRN1.SGM
09MRN1
Agencies
[Federal Register Volume 82, Number 45 (Thursday, March 9, 2017)]
[Notices]
[Page 13123]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04626]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces a meeting for the initial review of
applications in response to RFA-OH17-1701, Cooperative Agreement on
Global Occupational Health with the World Health Organization (WHO).
TIME AND DATE: 1:00 p.m.-5:00 p.m., EDT, April 11, 2017 (Closed).
PLACE: Teleconference.
STATUS: The meeting will be closed to the public in accordance with
provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C.,
and the Determination of the Director, Management Analysis and Services
Office, CDC, pursuant to Public Law 92-463.
MATTERS FOR DISCUSSION: The meeting will include the initial review,
discussion, and evaluation of applications received in response to
``Cooperative Agreement on Global Occupational Health with the World
Health Organization (WHO)'', RFA-OH17-1701.
CONTACT PERSON FOR MORE INFORMATION: Nina Turner, Ph.D., Scientific
Review Officer, NIOSH, CDC, 1095 Willowdale Road, Mailstop G905,
Morgantown, West Virginia 26506, Telephone: (304) 285-5976.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2017-04626 Filed 3-8-17; 8:45 am]
BILLING CODE 4163-18-P